LOINC
Version 2.73

13908-9Oxipurinol [Mass/volume] in Serum or PlasmaActive

Part Descriptions

LP18483-5   Oxipurinol
Oxypurinol is an inhibitor of xanthine oxidase. It is an active metabolite of allopurinol and it is cleared renally. In cases of renal disease, this metabolite will accumulate to toxic levels. Copyright Text is available under the Creative Commons Attribution/Share-Alike License. See http://creativecommons.org/licenses/by-sa/3.0/ for details. Source: Wikipedia, Oxypurinol

LP18483-5   Oxipurinol
Oxipurinol [alloxanthine, Oxyprim, oxypurinol] is the active metabolite of the only commercially available xanthine oxidase inhibitor, allopurinol. Oxipurinol is also a xanthine oxidase inhibitor. Oxipurinol is currently being developed by Cardiome Pharma. It is waiting for approval in the US for the treatment of allopurinol-intolerant hyperuricaemia (gout) and is in phase III trials for the treatment of congestive heart failure. Allopurinol is indicated for the treatment of symptomatic hyperuricaemia, or gout. Approximately 3-5% of patients receiving allopurinol develop intolerance to the drug. Oxipurinol was originally developed by Burroughs Wellcome (later GlaxoSmithKline), and has been available on a compassionate-use basis since 1967 for use in allopurinol-intolerant patients. The licensee company ILEX Oncology has stated that oxipurinol does not have patent protection. Oxipurinol's potential for treatment of congestive heart failure is based on the possibility that xanthine oxidase inhibitors may improve myocardial work efficiency by sensitising cardiac muscle cells to calcium ions, which are a key determinant of cardiac muscle function. This results in more efficient contraction of cardiac muscle cells, without the same increase in oxygen demand. At the second annual BioPartnering North America conference (BPN-2004) [February 2004, Vancouver, Canada], Cardiome Pharma stated that it was seeking a commercialisation partner to market and distribute oxipurinol in the US for the treatment of allopurinol-intolerant hyperuricaemia. [Drugs R D. 2004;5(3):171-5.] Source: NCBI PubMed, PMID:15139781

Fully-Specified Name

Component
Oxipurinol
Property
MCnc
Time
Pt
System
Ser/Plas
Scale
Qn
Method

Additional Names

Short Name
Oxipurinol SerPl-mCnc
Display Name
Oxipurinol [Mass/Vol]
Consumer Name Alpha
Oxipurinol, Blood

Basic Attributes

Class
DRUG/TOX
Type
Laboratory
First Released
Version 1.0k
Last Updated
Version 2.73
Order vs. Observation
Both
Common US Lab Results Rank
16015

Member of these Panels

LOINC Long Common Name
43133-8 Allopurinol and Oxipurinol panel [Mass/volume] - Serum or Plasma

Member of these Groups

LG1986-1 Oxipurinol|MCnc|Pt|ANYBldSerPl
LG46197-6 Oxipurinol|Pt|Ser/Plas|152.113 g/mole

Language Variants Get Info

zh-CNChinese (China)
奥昔嘌醇:质量浓度:时间点:血清/血浆:定量型:
nl-NLDutch (Netherlands)
oxipurinol:massa/volume:moment:serum of plasma:kwantitatief:
et-EEEstonian (Estonia)
Oksipurinool:MCnc:Pt:S/P:Qn:
fr-BEFrench (Belgium)
Oxipurinol:Concentration de masse:Temps ponctuel:Sérum/Plasma:Quantitatif:
fr-CAFrench (Canada)
Oxipurinol:Concentration de masse:Temps ponctuel:Sérum/Plasma:Quantitatif:
fr-FRFrench (France)
Oxipurinol:Masse/Volume:Ponctuel:Sérum/Plasma:Numérique:
it-ITItalian (Italy)
Ossipurinolo:MCnc:Pt:Siero/Plasma:Qn:
ko-KRKorean (Korea, Republic of)
Oxipurinol:질량농도:검사시점:혈청/혈장:정량:
pt-BRPortuguese (Brazil)
Oxipurinol:MCnc:Pt:Sor/Plas:Qn:
ru-RURussian (Russian Federation)
Оксипуринол:МассКонц:ТчкВрм:Сыв/Плаз:Колич:
es-ARSpanish (Argentina)
oxipurinol:concentración de masa:punto en el tiempo:suero/plasma:cuantitativo:
es-MXSpanish (Mexico)
Oxipurinol:Concentración de masa:Punto temporal:Suero o Plasma:Cuantitativo:
es-ESSpanish (Spain)
Oxipurinol:Concentración de masa:Punto temporal:Suero o Plasma:Qn:
tr-TRTurkish (Turkey)
Oksipürinol:KütlKons:Zmlı:Ser/Plaz:Kant:

Example Units

Unit Source
ug/mL Example UCUM Units

LOINC FHIR® API Example - CodeSystem Request Get Info

https://fhir.loinc.org/CodeSystem/$lookup?system=http://loinc.org&code=13908-9